<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02090140</url>
  </required_header>
  <id_info>
    <org_study_id>27561</org_study_id>
    <nct_id>NCT02090140</nct_id>
  </id_info>
  <brief_title>Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects</brief_title>
  <official_title>Randomized Controlled Trial of Microfracture Versus Adipose Derived Stem Cells for the Treatment of Isolated Articular Cartilage Defects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Kentucky</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two biologic methods for the treatment of articular
      cartilage defects in the knee. The first method, microfracture, is the standard of care and
      is routinely used to recruit cells from the subchondral bone marrow to the site of cartilage
      loss. The second method is the application of adipose-derived stem cells (ADSCs) to the
      defect site. In theory, ADSCs on a collagen scaffold should enable the delivery of more
      specific progenitor cells to the site of injury, resulting in better regeneration and
      integration of articular cartilage at the site of a defect as compared to the microfracture
      method.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients enrolled in the ADSC cohort will undergo the following procedures: arthroscopic
      resection of approximately 5cc of the infrapatellar fat pad using a motorized shaver
      (standard use in arthroscopy). Fat will be collected in a sterile Aquavage Collection System
      (AV1200, MD Resources, Livermore, CA) and kept sealed until processing. Fat will then
      immediately be processed in the Harvest Adiprep System to separate a population of ADSCs.
      This system concentrates an average of 5 x 105 cells/ml. All specimens will be processed
      using routine sterile procedures within the operating room; cells destined for implantation
      will not leave the operating room. Concurrently, patients will undergo arthroscopy and
      similar preparation of the chondral defect and removal of the calcified cartilage layer.
      However, no puncture of the subchondral bone will be performed. A layer of fibrin glue
      (Tisseel) will be placed at the base of the defect to seal off any bleeding from the
      subchondral plate followed by the application of the acellular dermal matrix (Allopatch HD,
      MTF Corporation, Edison, NJ, USA)and ADSCs. An additional layer of Tisseel will then be
      applied over the cells and matrix. No additional fixation will be applied. The matrix and
      cells will be recessed below the articular surface by an average of 1mm.

      They will then complete outcome questionnaires and additional MRI scans at 6, 12, and 24
      months post-operatively.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Health Scores on the KOOS Questionnaire</measure>
    <time_frame>Completed at baseline, 6 months, 12 months, and 24 months post-operatively.</time_frame>
    <description>The Knee Osteoarthritis Outcome Score (KOOS), a standard outcome questionnaire for the assessment of health-related quality of life, will be completed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Activity Level on the Tegner Activity Scale</measure>
    <time_frame>Completed at baseline, 6 months, 12 months, and 24 months post-operatively.</time_frame>
    <description>The Tegner Activity scale, a standard outcome questionnaire for assessment of activity levels, will be completed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cartilage Composition Assessment by MRI Scan</measure>
    <time_frame>Assessed at baseline, 6 months, 12 months, and 24 months post-operatively.</time_frame>
    <description>Magnetic resonance imaging scans consisting of routine clinical sequences and T2 and T1p quantitative maps will be conducted. T1p and T2 mapping will be used to assess regenerative cartilage composition compared to surrounding normal cartilage, surface integrity, average cartilage thickness, and the percentage to which the defect is filled.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functionality Scores on the Lysholm Scale</measure>
    <time_frame>Completed at baseline, 6 months, 12 months, and 24 months post-operatively.</time_frame>
    <description>The Lysholm Scale, a standard outcome questionnaire for assessment of knee functionality, will be completed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Scores on the Visual Analog Scale (VAS)</measure>
    <time_frame>Completed at baseline, 6 months, 12 months, and 24 months post-operatively.</time_frame>
    <description>The Visual Analog Scale, a standard outcome questionnaire for assessment of pain levels, will be completed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Scores on Veterans-Rand (VR-12) Survey</measure>
    <time_frame>Completed at baseline, 6 months, 12 months, and 24 months post-operatively.</time_frame>
    <description>The Veterans-Rand survey, a standard outcome questionnaire for assessment of health and quality of life, will be completed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Degenerative Lesion of Articular Cartilage of Knee</condition>
  <arm_group>
    <arm_group_label>ADSC Application</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo an arthroscopic surgical procedure, ADSC application, followed by physical therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microfracture Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo an arthroscopic surgical procedure, microfracture, followed by physical therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ADSC Application</intervention_name>
    <description>Patients will undergo arthroscopic resection of approximately 5cc of the infrapatellar fat pad, which will be collected for processing for a population of ADSCs. Patients will undergo arthroscopy and preparation of the chondral defect and removal of the calcified cartilage layer. Tisseel Fibrin glue will be placed at the base of the defect side, followed by the application of the acellular collagen dermal matrix, ADSCs, and an additional layer of fibrin glue.</description>
    <arm_group_label>ADSC Application</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Microfracture</intervention_name>
    <description>Microfracture surgery is the standard of care for articular cartilage lesions. Patients will undergo arthroscopy with standard technique of microfracture preparation, including the creation of vertical, stable defect edges and removal of the calcified cartilage layer. A microfracture awl will then be used to perform the microfracture technique (6mm below the subchondral plate).</description>
    <arm_group_label>Microfracture Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be between ages 18 and 50 years.

          -  Must have a discrete, contained chondral defect less than 400mm^2 located on the
             medial or lateral femoral condyle

          -  Must have overall neutral lower limb mechanical alignment (&lt;5 degrees varus or
             valgus).

        Exclusion Criteria:

          -  Ages younger than 18 years and older than 50 years.

          -  If they have undergone previous chondral procedures

          -  If they have pre-existing osteoarthritis (Kellegren-Lawrence Grade ≥2)

          -  If they have a BMI &gt;30.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Dragoo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Backer</last_name>
    <phone>(650) 721-7653</phone>
    <email>mbacker@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>JR Yabut</last_name>
    <phone>(650) 721-7780</phone>
    <email>jayabut@stanfordmed.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford Medical Outpatient Center</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Yabut</last_name>
      <phone>650-721-7780</phone>
      <email>jayabut@stanfordmed.org</email>
    </contact>
    <investigator>
      <last_name>Jason Dragoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bedi A, Feeley BT, Williams RJ 3rd. Management of articular cartilage defects of the knee. J Bone Joint Surg Am. 2010 Apr;92(4):994-1009. doi: 10.2106/JBJS.I.00895. Review.</citation>
    <PMID>20360528</PMID>
  </reference>
  <reference>
    <citation>Knutsen G, Engebretsen L, Ludvigsen TC, Drogset JO, Grøntvedt T, Solheim E, Strand T, Roberts S, Isaksen V, Johansen O. Autologous chondrocyte implantation compared with microfracture in the knee. A randomized trial. J Bone Joint Surg Am. 2004 Mar;86-A(3):455-64.</citation>
    <PMID>14996869</PMID>
  </reference>
  <reference>
    <citation>Dragoo JL, Samimi B, Zhu M, Hame SL, Thomas BJ, Lieberman JR, Hedrick MH, Benhaim P. Tissue-engineered cartilage and bone using stem cells from human infrapatellar fat pads. J Bone Joint Surg Br. 2003 Jul;85(5):740-7.</citation>
    <PMID>12892203</PMID>
  </reference>
  <reference>
    <citation>English A, Jones EA, Corscadden D, Henshaw K, Chapman T, Emery P, McGonagle D. A comparative assessment of cartilage and joint fat pad as a potential source of cells for autologous therapy development in knee osteoarthritis. Rheumatology (Oxford). 2007 Nov;46(11):1676-83. Epub 2007 Sep 26.</citation>
    <PMID>17901063</PMID>
  </reference>
  <reference>
    <citation>Koh YG, Choi YJ. Infrapatellar fat pad-derived mesenchymal stem cell therapy for knee osteoarthritis. Knee. 2012 Dec;19(6):902-7. doi: 10.1016/j.knee.2012.04.001. Epub 2012 May 14.</citation>
    <PMID>22583627</PMID>
  </reference>
  <reference>
    <citation>Ma A, Jiang L, Song L, Hu Y, Dun H, Daloze P, Yu Y, Jiang J, Zafarullah M, Chen H. Reconstruction of cartilage with clonal mesenchymal stem cell-acellular dermal matrix in cartilage defect model in nonhuman primates. Int Immunopharmacol. 2013 Jul;16(3):399-408. doi: 10.1016/j.intimp.2013.02.005. Epub 2013 Mar 13.</citation>
    <PMID>23499511</PMID>
  </reference>
  <reference>
    <citation>Giavaresi G, Bondioli E, Melandri D, Giardino R, Tschon M, Torricelli P, Cenacchi G, Rotini R, Castagna A, Veronesi F, Pagani S, Fini M. Response of human chondrocytes and mesenchymal stromal cells to a decellularized human dermis. BMC Musculoskelet Disord. 2013 Jan 7;14:12. doi: 10.1186/1471-2474-14-12.</citation>
    <PMID>23294867</PMID>
  </reference>
  <reference>
    <citation>Desando G, Cavallo C, Sartoni F, Martini L, Parrilli A, Veronesi F, Fini M, Giardino R, Facchini A, Grigolo B. Intra-articular delivery of adipose derived stromal cells attenuates osteoarthritis progression in an experimental rabbit model. Arthritis Res Ther. 2013 Jan 29;15(1):R22. doi: 10.1186/ar4156.</citation>
    <PMID>23360790</PMID>
  </reference>
  <reference>
    <citation>Koh YG, Jo SB, Kwon OR, Suh DS, Lee SW, Park SH, Choi YJ. Mesenchymal stem cell injections improve symptoms of knee osteoarthritis. Arthroscopy. 2013 Apr;29(4):748-55. doi: 10.1016/j.arthro.2012.11.017. Epub 2013 Jan 29.</citation>
    <PMID>23375182</PMID>
  </reference>
  <reference>
    <citation>Wickham MQ, Erickson GR, Gimble JM, Vail TP, Guilak F. Multipotent stromal cells derived from the infrapatellar fat pad of the knee. Clin Orthop Relat Res. 2003 Jul;(412):196-212.</citation>
    <PMID>12838072</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2014</study_first_submitted>
  <study_first_submitted_qc>March 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2014</study_first_posted>
  <last_update_submitted>September 29, 2017</last_update_submitted>
  <last_update_submitted_qc>September 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Jason L. Dragoo</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>cartilage/transplantation</keyword>
  <keyword>cartilage, articular/injuries</keyword>
  <keyword>cartilage, articular/surgery</keyword>
  <keyword>chondrocytes/cytology</keyword>
  <keyword>knee injuries/surgery</keyword>
  <keyword>knee joint/surgery</keyword>
  <keyword>orthopedic procedures/methods</keyword>
  <keyword>tissue engineering</keyword>
  <keyword>tissue scaffolds</keyword>
  <keyword>arthroscopy/methods</keyword>
  <keyword>chondrocytes/transplantation</keyword>
  <keyword>adipose tissue/cytology</keyword>
  <keyword>cartilage, articular/cytology</keyword>
  <keyword>chondrogenesis/physiology</keyword>
  <keyword>osteogenesis/physiology</keyword>
  <keyword>stem cell transplantation/methods</keyword>
  <keyword>stem cells</keyword>
  <keyword>tissue engineering/methods</keyword>
  <keyword>cartilage, articular/pathology</keyword>
  <keyword>chondrocytes/pathology</keyword>
  <keyword>knee joint/pathology</keyword>
  <keyword>platelet-rich plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Stress</mesh_term>
    <mesh_term>Cartilage Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

